NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 242)
Posted On: 04/16/2020 3:55:35 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) and RedShiftBio Combine Proprietary Technology to Create Powerful Biotherapeutic Drug Development Platform
Pressure BioScience (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the worldwide life sciences and other industries, today announced that the combination of PBIO’s patented Pressure Cycling Technology (“PCT”) with RedShiftBio’s proprietary Microfluidic Modulation Spectroscopy (“MMS”) has resulted in a powerful new platform for biotherapeutic drug development (“PCT-enhanced MMS”). PBIO believes combining both platforms enables for the rigorous investigation of protein structure and stability in a highly efficient workflow that can be crucial in drug development. Per the release, the collaboration should result in faster development of new drugs as well as improvement in the quality of drugs coming onto the market. “Our collaboration with RedShiftBio takes advantage of our ability to manipulate protein structure with high pressure and RedShiftBio’s precise analytical platform that reports subtle changes in the three-dimensional structure of protein molecules that could lead to protein aggregation. Unfortunately, aggregated protein biologics could train a patient’s immune system to recognize and eliminate the drug, so finding appropriate formulations to prevent aggregation is a major task in biopharmaceutical drug development. Moreover, MMS will help us to understand protein folding kinetics in our BaroFold platform, which uses high pressure to shape recombinant proteins into their active and stable conformations in biomanufacturing process development,” Alexander V. Lazarev, Ph.D., Chief Science Officer of PBIO stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioScience (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the worldwide life sciences and other industries, today announced that the combination of PBIO’s patented Pressure Cycling Technology (“PCT”) with RedShiftBio’s proprietary Microfluidic Modulation Spectroscopy (“MMS”) has resulted in a powerful new platform for biotherapeutic drug development (“PCT-enhanced MMS”). PBIO believes combining both platforms enables for the rigorous investigation of protein structure and stability in a highly efficient workflow that can be crucial in drug development. Per the release, the collaboration should result in faster development of new drugs as well as improvement in the quality of drugs coming onto the market. “Our collaboration with RedShiftBio takes advantage of our ability to manipulate protein structure with high pressure and RedShiftBio’s precise analytical platform that reports subtle changes in the three-dimensional structure of protein molecules that could lead to protein aggregation. Unfortunately, aggregated protein biologics could train a patient’s immune system to recognize and eliminate the drug, so finding appropriate formulations to prevent aggregation is a major task in biopharmaceutical drug development. Moreover, MMS will help us to understand protein folding kinetics in our BaroFold platform, which uses high pressure to shape recombinant proteins into their active and stable conformations in biomanufacturing process development,” Alexander V. Lazarev, Ph.D., Chief Science Officer of PBIO stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼